A5080037221- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Testicular diseases and treatments
- Prostate Cancer Treatment and Research
- Renal and related cancers
- Sarcoma Diagnosis and Treatment
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Sperm and Testicular Function
- Sexual Differentiation and Disorders
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Esophageal Cancer Research and Treatment
- Pediatric Urology and Nephrology Studies
- Male Reproductive Health Studies
- Genital Health and Disease
- Cancer Diagnosis and Treatment
- Urinary Bladder and Prostate Research
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare Policy and Management
- Epigenetics and DNA Methylation
The University of Texas Southwestern Medical Center
2016-2025
Southwestern Medical Center
2016-2025
Southern California University for Professional Studies
2023
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2023
University of Southern California
2023
University of California, San Diego
2023
University of Cambridge
2023
Puigvert Foundation
2022
John Wiley & Sons (United States)
2021
John Peter Smith Hospital
2020
Most kidney cancers are metabolically dysfunctional
Abstract In prostate cancer, androgen deprivation therapy (ADT) enhances the cytotoxic effects of radiotherapy. This effect is associated with weakening DNA damage response (DDR) normally supported by receptor. As a significant number patients will fail combined ADT and radiotherapy, we hypothesized that DDR may be driven receptor splice variants (ARV) induced ADT. Investigating this hypothesis, found ARVs increase clonogenic survival cancer cells after irradiation in an ADT-independent...
We evaluated the discordance between ureteroscopic biopsy and surgical pathology findings for grading staging upper tract urothelial carcinoma. also sought to establish preoperative predictors of aggressive tumors.We retrospectively reviewed records 314 patients who underwent followed by management carcinoma from 2000 2016 at a total 3 institutions. Our primary outcomes were muscle invasive (pT2 or greater) disease upgrading clinical low grade tumors pathological high grade.At 61% had 21%...
Existing tumor markers for testicular germ cell (TGCT) cannot detect the presence of pure teratoma. Serum miRNAs have strong performance detecting other subtypes TGCT. Previous reports suggest high levels miR-375 expression in teratoma tissue. The purpose this study was to explore role serum miRNA, including miR-375, at postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). We prospectively collected presurgical from 40 TGCT patients undergoing PC-RPLND (21 with RPLND and 19 no...
Circulating miR-371a-3p has excellent performance in the detection of viable (non-teratoma) germ cell tumor (GCT) pre-orchiectomy; however, its ability to detect occult disease is understudied. To refine serum assay minimal residual setting we compared raw (Cq) and normalized (∆Cq, RQ) values from prior assays, validated interlaboratory concordance by aliquot swapping. Revised was determined a cohort 32 patients suspected retroperitoneal disease. Assay superiority comparing resulting...
We investigated the prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma.Tissue microarrays 423 treated extirpative surgery for carcinoma from International Upper Tract Urothelial Carcinoma collaboration were stained using antibodies, including Cell Marque™ NAT105 diluted 1:250 prediluted E1L3N® via immunohistochemistry. A 1% or greater staining rate tumor infiltrating lymphocytes (PD-1) cells (PD-L1) was considered positive. Univariate...
Current serum tumor markers for testicular germ cell are limited by low sensitivity. Growing evidence supports the use of circulating miR-371a-3p as a superior marker malignant (viable) management. We evaluated real-world application levels in detecting viable among patients undergoing partial or radical orchiectomy.
Objective To quantify the oncological risks of bladder‐sparing therapy (BST) in patients with Bacillus Calmette–Guérin (BCG)‐unresponsive non‐muscle‐invasive bladder cancer (NMIBC) compared to upfront radical cystectomy (RC). Patients and Methods Pre‐specified data elements were collected from retrospective cohorts BCG‐unresponsive NMIBC 10 international sites. After Institutional Review Board approval, included if they had meeting United States Food Drug Administration criteria. Oncological...
While robot-assisted radical prostatectomy (RARP) is associated with shortened convalescence and decreased blood loss over open prostatectomy, little objective data available regarding postoperative pain/discomfort use of analgesic medications after RARP. We sought to examine these parameters in a contemporary cohort.From 2011 2013, patients undergoing RARP were prospectively enrolled study various pain carefully monitor opiate other medication while the patient recovered hospital. After...
Small renal masses (SRM) can be managed via a variety of nephron-sparing procedures (NSPs), but the association between choice NSP and parenchymal volume (RPV) preservation is not well understood. We sought to examine RPV after partial nephrectomy (PN) performed open, robotic, or laparoscopic approaches thermal ablation (TA) cryoablation (CA) radiofrequency (RFA).The study was retrospective review three institutional databases patients with SRM <4 cm treated one five NSPs (open PN, robotic...
Summary Most kidney cancers display evidence of metabolic dysfunction 1–4 but how this relates to cancer progression in humans is unknown. We used a multidisciplinary approach infuse 13 C-labeled nutrients during surgical tumour resection over 70 patients with cancer. Labeling from [U- C]glucose varies across subtypes, indicating that the environment alone cannot account for all reprogramming these tumours. Compared adjacent kidney, clear cell renal carcinomas (ccRCC) suppressed labelling...